A European perspective on the Canadian guidelines for bipolar disorder

Bipolar Disorders, Supplement

Volumn 7, Issue 3, 2005, Pages 73-76

  Vieta, Eduard ^a   Nolen, Willem A ^b   Grunze, Heinz ^c   Licht, Rasmus W ^d   Goodwin, Guy ^e  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d AARHUS UNIVERSITY   (Denmark)

^e WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; HALOPERIDOL; LITHIUM; OLANZAPINE; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; CANADA; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; EUROPE; HIGH RISK POPULATION; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICAL SPECIALIST; NOTE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL;

EID: 23044447752     PISSN: 13992406     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2005.00221.x     Document Type: Note

References (32)

1. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision) Am J Psychiatry 2002; 159 (Suppl. 4): 1-50.
2. Grunze H, Kasper S, Goodwin G et al. World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: treatment of bipolar depression. World J Biol Psychiatry 2002; 3: 115-124.
3. Grunze H, Kasper S, Goodwin G et al. WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders. Part II: treatment of mania. World J Biol Psychiatry 2003; 4: 5-13.
4. Grunze H, Kasper S, Goodwin G, Bowden C, Moller HJ. WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders. Part III: maintenance treatment. World J Biol Psychiatry 2004; 5: 120-135.
5. Calabrese JR, Kasper S, Johnson G et al. International Consensus Group on Bipolar I Depression Treatment Guidelines. J Clin Psychiatry 2004; 65: 571-579.
6. Licht RW, Vestergaard P, Kessing LV, Larsen JK, Thomsen PH. Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Psychopharmacological treatment with lithium and antiepileptic drugs: suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Acta Psychiatr Scand Suppl 2003; 419: 1-22.
7. Goodwin GM. Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003; 17: 149-173.
8. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust N Z J Psychiatry 2004; 38: 280-305.
9. Suppes T, Rush AJ, Dennehy EB et al. Texas Medication Algorithm Project. Texas Medication Algorithm Project, phase 3 (TMAP-3): clinical results for patients with a history of mania. J Clin Psychiatry 2003; 64: 370-382.
10. Vieta E, Colom F. Psychological interventions in bipolar disorder: from wishful thinking to an evidence-based approach. Acta Psychiatr Scand Suppl 2004; 422: 34-38.
11. Yatham LN, Kennedy S, O'Donovan C et al. Canadian Network for Mood and Anxiety Disorders: Guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; in press.
12. Vieta E, Carne X. The use of placebo in clinical trials on bipolar disorder: a new approach for an old debate. Psychother Psychosom 2005; 74: 10-16.
13. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000; 157: 124-126.
14. Calabrese J, Keck P, Macfadden W, et al. A randomized double-blind placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry in press.
15. Himmelhoch JM, Fuchs CZ, Symons BJ. A double-blind study of tranylcypromine treatment of major anergic depression. J Nerv Ment Dis 1982; 170: 628-634.
16. Himmelhoch JM, Thase M, Mallinger A, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910-916.
17. Vieta E. Olanzapine in bipolar disorder. Expert Opin Pharmacother 2004; 5: 1613-1619.
18. Vestergaard P. Guidelines for maintenance treatment of bipolar disorder: are there discrepancies between European and North American recommendations? Bipolar Disord 2004; 6: 519-522.
19. Vieta E. Atypical antipsychotics in the treatment of mood disorders. Curr Opin Psychiatry 2003; 16: 23-27.
20. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004; 161: 1537-1547.
21. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 2003; 5: 421-433.
22. Altshuler L, Suppes T, Black D et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003; 160: 1252-1262.
23. Vieta E. Case for caution, case for action. Bipolar Disord 2003; 5: 434-435.
24. Goodwin GM, Bowden CL, Calabrese JR et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65: 432-441.
25. Greil W, Ludwig-Mayerhofer W, Erazo N et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study. J Affect Disord 1997; 43: 151-161.
26. Hartong EG, Moleman P, Hoogduin CA, Broekman TG, Nolen WA. LitCar Group. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003; 64: 144-151.
27. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 290: 1467-1473.
28. Viguera AC, Nonacs R, Cohen LS, Tondo L, Murray A, Baldessarini RJ. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000; 157: 179-184.
29. Yonkers KA, Wisner KL, Stowe Z et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161: 608-620.
30. Rasgon N, Altshuler LL, Fairbanks L et al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005; in press.
31. Tohen M, Ketter TA, Zarate CA et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003; 160: 1263-1271.
32. Fountoulakis KN, Vieta E, Sanchez-Moreno J, Kaprinis SG, Goikolea JM, Kaprinis GS. Treatment guidelines for bipolar disorder: a critical review. J Affect Disord 2005; 86: 1-10.